Dr. Sonya Reid introduces the program by outlining the objectives of the discussion, which focus on the expanding role of genomic testing in the management of early-stage HR-positive, HER2-negative breast cancer.
Optimizing Treatment Decision-Making in Early-Stage Breast Cancer: Integrating Genomic Testing into Clinical Practice
Advertisement
Advertisement
Trending on OncLive
1
T-DXd Wins EU Approval for Previously Treated, HER2+ Metastatic Solid Tumors
2
Elisrasib Yields Durable Responses in Pretreated KRAS G12C–Mutant NSCLC Regardless of Prior G12C Inhibitor Use
3
FDA Issues CRL to PET Diagnostic Imaging Kit for Gallium-68 Edotreotide in SSTR+ NETs
4
Dr Thomas on the Efficacy of First-Line Ipatasertib Plus Pembrolizumab in HNSCC
5